Q&A: New drug being reviewed by the FDA to treat Parkinson's disease

The U.S. Food and Drug Administration is reviewing a new Parkinson's disease drug called tavapadon that could give people ...
Nasdaq

RHHBY to Advance Parkinson's Disease Drug to Late-Stage Development

Roche RHHBY announced that it will advance pipeline candidate prasinezumab into phase III development for early-stage Parkinson’s disease. Roche has a licensing agreement with Prothena PRTA for ...
KHON2

Arvinas Presents Late Breaking, Positive Phase 1 Clinical Data for ARV-102, a PROTAC LRRK2 Degrader, at the 2025 International Congress of Parkinson’s Disease and Movement ...

– After 14 days of treatment in healthy volunteers, ARV-102 decreased lysosomal and neuroinflammatory microglial pathway biomarkers known to be elevated in Parkinson’s disease – NEW HAVEN, Conn., Oct.
Yahoo

Parkinson's Disease Could Be Ignited by Burned-Out Brain Cells

Parkinson's disease is characterized by the death of dopamine-producing neurons in a part of the brain responsible for motor movement. Now there's fresh evidence for how these crucial brain cells are ...
Nasdaq

Genentech Advances Prasinezumab To Phase III Trials In Early Parkinson's Disease

(RTTNews) - Genentech, a member of the Roche Group (RHHBY), announced its decision to advance prasinezumab—a potential anti-alpha-synuclein antibody—into Phase III clinical development for early-stage ...